ArticleBMC cancer2025
Nomogram models for prediction of axillary lymph node metastasis in breast cancer patients.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe purpose of this study was to establish two preoperative nomogram models to evaluate the status of axillary lymph nodes (ALNs) in early breast cancer patients based on ultrasound data, PET/CT data, and clinicopathological features. Accordingly, more appropriate treatment strategies for breast cancer patients could be selected.
methodsFrom April 2017 to April 2023, a total of 254 patients from the Clinical Data Research (CDR) database of Peking Union Medical College Hospital were included in this study and randomly assigned to the training and internal testing groups at a ratio of 8:2, with outcome variables being axillary lymph nodes metastasis (ALNM) and high nodal tumour burden (HNTB). The predictive factors determined by Least Absolute Shrinkage and Selection Operator (LASSO) regression and multivariate logistic regression analyses were used to construct the nomograms. Receiver operating characteristic (ROC) curves and calibration plots were used to assess the prediction models' discrimination and calibration.
resultsLASSO regression and multivariate logistic regression analyses showed that Plnsuv (PET/CT lymph node SUVmax), unclear cortico-medullary delineation and Progesterone Receptor (PR) positive were independent predictors of ALNM. Moreover, Plnsuv, tumour size and Her-2 positive were independent predictors of HNTB, respectively. Integrating these independent predictors, two nomograms were successfully developed to accurately predict the status of ALN. For nomogram 1 (prediction of ALNM), the area under the ROC curve in the testing group was 0.889. For nomogram 2 (prediction of HNTB), the area under the ROC curve in the testing group was 0.784. The above results showed a satisfactory performance.
conclusionsWe developed two preoperative nomograms that can be used to predict ALN metastasis (LN - vs. LN+) and the number of metastatic ALNs (≤ 2 vs. >2) in early breast cancer patients. They were well verified in internal testing groups. The nomograms can help clinicians predict the status of ALNs and guide discussions regarding axillary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.